Cantor Fitzgerald set a $7.00 price target on Egalet (NASDAQ:EGLT) in a research report report published on Tuesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

EGLT has been the subject of several other research reports. Gabelli downgraded Egalet from a buy rating to a hold rating in a research report on Thursday, November 9th. Stifel Nicolaus reiterated a buy rating and issued a $6.00 price target (down previously from $14.00) on shares of Egalet in a research note on Thursday, August 10th. Finally, Guggenheim set a $7.00 price target on Egalet and gave the stock a buy rating in a research note on Monday, August 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $7.10.

Shares of Egalet (NASDAQ:EGLT) opened at $1.27 on Tuesday. Egalet has a 1 year low of $0.80 and a 1 year high of $10.00. The company has a debt-to-equity ratio of -3.43, a quick ratio of 2.68 and a current ratio of 2.73.

Several large investors have recently added to or reduced their stakes in EGLT. KCG Holdings Inc. lifted its stake in shares of Egalet by 81.0% in the first quarter. KCG Holdings Inc. now owns 42,722 shares of the specialty pharmaceutical company’s stock worth $218,000 after acquiring an additional 19,116 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Egalet by 1.1% in the second quarter. Janney Montgomery Scott LLC now owns 45,963 shares of the specialty pharmaceutical company’s stock worth $109,000 after acquiring an additional 500 shares in the last quarter. New Jersey Better Educational Savings Trust lifted its stake in shares of Egalet by 4.0% in the second quarter. New Jersey Better Educational Savings Trust now owns 104,000 shares of the specialty pharmaceutical company’s stock worth $246,000 after acquiring an additional 4,000 shares in the last quarter. LMR Partners LLP acquired a new position in shares of Egalet in the second quarter worth about $179,000. Finally, Virtu KCG Holdings LLC raised its stake in Egalet by 87.0% during the second quarter. Virtu KCG Holdings LLC now owns 79,877 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 37,155 shares in the last quarter. Institutional investors and hedge funds own 54.24% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/02/egalet-eglt-given-a-7-00-price-target-at-cantor-fitzgerald.html.

About Egalet

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Analyst Recommendations for Egalet (NASDAQ:EGLT)

Receive News & Stock Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related stocks with our FREE daily email newsletter.